论文部分内容阅读
目的评价并比较两种化疗方案在晚期非小细胞肺癌治疗中的临床疗效以及药物经济学指标。方法选取晚期非小细胞肺癌行化疗的患者63例,随机分为观察组31例与对照组32例。观察组选用多西他赛联合顺铂(DP)方案治疗,对照组选用紫杉醇联合顺铂(TP)治疗,观察并比较2组临床疗效及各项药物经济学指标。结果观察组总有效率为45.2%,高于对照组的25.0%,但2组比较差异无统计学意义(P>0.05)。观察组化疗成本与有效率之比为39 681,远小于对照组的55 540,差异有统计学意义(P<0.05)。2组不良反应发生率比较差异无统计学意义(P>0.05)。结论多西他赛联合顺铂与紫杉醇联合顺铂对于晚期非小细胞肺癌患者均有较好的治疗效果,且安全性良好,但通过成本—效果分析发现,多西他赛联合顺铂组更加经济有效。
Objective To evaluate and compare the clinical efficacy of two chemotherapy regimens in the treatment of advanced non-small cell lung cancer and their pharmacological and economic indicators. Methods Sixty-three patients with advanced non-small cell lung cancer undergoing chemotherapy were randomly divided into observation group (n = 31) and control group (n = 32). The observation group was treated with docetaxel combined with cisplatin (DP). The control group was treated with paclitaxel combined with cisplatin (TP). The clinical efficacy and various pharmacological indexes of the two groups were observed and compared. Results The total effective rate in observation group was 45.2%, which was higher than that in control group (25.0%), but there was no significant difference between two groups (P> 0.05). The ratio of chemotherapy cost to effective rate in the observation group was 39 681, much smaller than that in the control group 55 540 (P 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion Docetaxel combined with cisplatin and paclitaxel combined with cisplatin in patients with advanced non-small cell lung cancer have a good effect, and good safety, but cost-effectiveness analysis found that docetaxel combined with cisplatin group more Cost-effective.